Company profile
Access Pharmaceuticals company profile
Access Pharmaceuticals (ACCP.ob) is an emerging pharmaceuticals company with a focus on oncology and diabetes. Access has one FDA approved treatment for oral mucositis (MuGard) which has been launched commercially in Europe and will be launched elsewhere in 2009. ProLindac, a novel DACH platinum chemotherapy, recently completed a Phase 2a trial in recurrent ovarian cancer and will enter combination trials shortly; ProLindac is partnered in the Far East and ACCP is actively seeking North American and European co-development partners. Additionally, ACCP has a novel nucleoside analogue, Thiarabine, which will enter Phase 2 leukemia trials this year, a preclinical stage monoclonal..... For more information, log in to dureach.com to view the full company profile.
Business identity
- Website
- http://accesspharma.com
- Contact email
- [email protected]
- Phone number
- 8774846946
- Operating status
- Closed
- Company type
- For Profit
- Employee range
- 00011-00050 employees
- Revenue range
- $0+
- Founded
- 1974-01-01
Headquarters
- Headquarters
- Wright City, Oklahoma, United States
- Postal code
- 75207
- Country code
- US
- Continent
- North America